Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study. (2020). SKIN The Journal of Cutaneous Medicine, 4(1), S2. https://skin.dermsquared.com/skin/article/view/801